NASDAQ:GWPH - GW Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $188.09
  • Forecasted Upside: 38.58 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$135.73
▼ -2.1 (-1.52%)
1 month | 3 months | 12 months
Get New GW Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GWPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GWPH

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$188.09
▲ +38.58% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for GW Pharmaceuticals in the last 3 months. The average price target is $188.09, with a high forecast of $275.00 and a low forecast of $128.00. The average price target represents a 38.58% upside from the last price of $135.73.
Buy
The current consensus among 12 contributing investment analysts is to buy stock in GW Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/25/2019
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2019
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2020
  • 0 strong buy ratings
  • 14 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/20/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/19/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/17/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/16/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/15/2021

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/29/2020Cantor FitzgeraldLower Price TargetOverweight$165.00 ➝ $147.00N/A
i
11/4/2020HC WainwrightReiterated RatingBuyLow
i
Rating by D. Tsao at HC Wainwright
8/24/2020Raymond JamesInitiated CoverageMarket PerformHigh
i
8/10/2020GuggenheimLower Price TargetBuy$160.00 ➝ $155.00Medium
i
8/7/2020The Goldman Sachs GroupSet Price TargetBuy ➝ In-Line$171.00 ➝ $271.00High
i
Rating by Salveen Richter, CFA at The Goldman Sachs Group, Inc.
8/7/2020Bank of AmericaReiterated RatingBuy$234.00High
i
8/7/2020Needham & Company LLCLower Price TargetBuy$190.00 ➝ $180.00High
i
8/4/2020HC WainwrightBoost Price TargetBuy$161.00 ➝ $164.00Medium
i
8/3/2020OppenheimerReiterated RatingBuy$166.00 ➝ $183.00Medium
i
Rating by Francois Brisebois at Oppenheimer Holdings Inc.
8/3/2020Cantor FitzgeraldBoost Price TargetOverweight$160.00 ➝ $165.00Low
i
Rating by C. Duncan at Cantor Fitzgerald
7/14/2020Stifel NicolausDowngradeBuy ➝ Hold$150.00 ➝ $140.00High
i
6/30/2020Evercore ISIBoost Price TargetOutperform$250.00 ➝ $275.00Low
i
Rating by Joshua Schimmer at Evercore ISI
5/29/2020OppenheimerInitiated CoverageBuy$173.00 ➝ $166.00Low
i
Rating by Francois Brisebois at Oppenheimer Holdings Inc.
5/14/2020Cantor FitzgeraldBoost Price TargetOverweight$120.00 ➝ $154.00High
i
Rating by C. Duncan at Cantor Fitzgerald
5/12/2020Needham & Company LLCReiterated RatingBuy$190.00Medium
i
4/8/2020Northland SecuritiesInitiated CoverageOutperform$128.00High
i
3/5/2020CitigroupInitiated CoverageBuy$192.00Medium
i
2/27/2020HC WainwrightLower Price TargetBuy$170.00 ➝ $161.00High
i
Rating by Douglas Tsao at HC Wainwright
2/26/2020Cantor FitzgeraldReiterated RatingBuy$174.00High
i
Rating by Charles Duncan at Cantor Fitzgerald
2/26/2020Bank of AmericaLower Price TargetBuy$233.00 ➝ $227.00High
i
2/26/2020OppenheimerLower Price TargetOutperform$203.00 ➝ $173.00Low
i
Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
2/26/2020Needham & Company LLCLower Price TargetBuy$200.00 ➝ $190.00High
i
Rating by Serge Belanger at Needham & Company LLC
2/7/2020Evercore ISIInitiated CoverageBuy$260.00Medium
i
Rating by Joshua Schimmer at Evercore ISI
1/2/2020JPMorgan Chase & Co.Initiated CoverageOverweight$134.00Low
i
12/18/2019HC WainwrightReiterated RatingBuy$170.00Low
i
Rating by Douglas Tsao at HC Wainwright
11/11/2019Evercore ISIReiterated RatingBuyMedium
i
11/8/2019HC WainwrightReiterated RatingBuyLow
i
Rating by D. Tsao at HC Wainwright
11/6/2019Cantor FitzgeraldReiterated RatingOverweight$174.00 ➝ $174.00Low
i
11/6/2019OppenheimerLower Price TargetOutperform$222.00Low
i
Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
10/30/2019HC WainwrightInitiated CoverageBuy$170.00Low
i
Rating by D. Tsao at HC Wainwright
10/21/2019Needham & Company LLCInitiated CoverageBuy$200.00Medium
i
9/27/2019OppenheimerLower Price TargetOutperform$239.00 ➝ $233.00Low
i
Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
9/25/2019Bank of AmericaReiterated RatingBuy$218.00Medium
i
8/7/2019Morgan StanleyBoost Price TargetOverweight$238.00Low
i
Rating by David Lebovitz at Morgan Stanley
8/7/2019OppenheimerBoost Price TargetBuy$234.00 ➝ $239.00Low
i
7/26/2019CowenReiterated RatingBuy$200.00Medium
i
5/8/2019OppenheimerDowngradeOutperform ➝ Market Perform$195.00Low
i
Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
5/8/2019JPMorgan Chase & Co.UpgradeMarket Perform ➝ OutperformLow
i
5/7/2019GuggenheimReiterated RatingBuy ➝ Buy$186.00 ➝ $222.00Low
i
Rating by Yatin Suneja at Guggenheim
5/7/2019CIBCUpgradeMarket Perform ➝ OutperformHigh
i
5/7/2019Piper Jaffray CompaniesBoost Price TargetOverweight$185.00 ➝ $210.00High
i
5/7/2019JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$180.00 ➝ $215.00High
i
5/7/2019Cantor FitzgeraldReiterated RatingPositive ➝ Overweight$196.00 ➝ $229.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
5/7/2019OppenheimerUpgradeMarket Perform ➝ Outperform$162.00 ➝ $234.00High
i
Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
4/29/2019OppenheimerBoost Price Target$142.00 ➝ $162.00Low
i
Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
4/9/2019Morgan StanleyReiterated RatingBuyLow
i
Rating by David Lebovitz at Morgan Stanley
3/18/2019Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$193.00 ➝ $196.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
2/27/2019Cantor FitzgeraldReiterated RatingBuy$193.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
2/27/2019Piper Jaffray CompaniesReiterated RatingOverweight$185.00High
i
2/22/2019GuggenheimInitiated CoverageBuy$178.00High
i
1/7/2019AltaCorp CapitalReiterated RatingOutperformMedium
i
Rating by D. Kideckel at AltaCorp Capital
1/2/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$134.00High
i
12/11/2018OppenheimerInitiated CoverageHold$142.00 ➝ $142.00Low
i
Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
12/9/2018Cantor FitzgeraldLower Price Target$211.00 ➝ $193.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
12/4/2018Cantor FitzgeraldReiterated RatingOverweightLow
i
Rating by Elemer Piros at Cantor Fitzgerald
12/3/2018Cantor FitzgeraldLower Price TargetOverweight ➝ Buy$211.00 ➝ $193.00Medium
i
Rating by Elemer Piros at Cantor Fitzgerald
11/27/2018Cantor FitzgeraldSet Price TargetBuy$211.00Medium
i
Rating by Elemer Piros at Cantor Fitzgerald
11/12/2018SVB LeerinkInitiated CoverageOutperform$185.00Low
i
Rating by M. Goodman at SVB Leerink LLC
11/5/2018Piper Jaffray CompaniesReiterated RatingOverweight ➝ OverweightLow
i
10/11/2018Morgan StanleySet Price TargetBuy$240.00 ➝ $227.00High
i
Rating by David Lebovitz at Morgan Stanley
9/28/2018Bank of AmericaReiterated RatingBuy ➝ Buy$181.00 ➝ $197.00Medium
i
9/28/2018Morgan StanleyBoost Price TargetOverweight$197.00 ➝ $240.00High
i
Rating by David Lebovitz at Morgan Stanley
9/27/2018Cantor FitzgeraldSet Price TargetBuy$211.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
9/7/2018Morgan StanleySet Price TargetOverweight ➝ Overweight$197.00Medium
i
8/14/2018Stifel NicolausInitiated CoverageBuy$181.00Medium
i
8/8/2018Cantor FitzgeraldLower Price TargetOverweight$235.00 ➝ $211.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
7/12/2018Cantor FitzgeraldSet Price TargetBuy$235.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
6/26/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$170.00 ➝ $200.00High
i
5/9/2018CowenReiterated RatingBuy$165.00Low
i
4/19/2018Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$192.00 ➝ $205.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
4/17/2018Cantor FitzgeraldSet Price TargetBuy$192.00Medium
i
Rating by Elemer Piros at Cantor Fitzgerald
2/21/2018Cantor FitzgeraldSet Price TargetBuy$192.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
2/6/2018Bank of AmericaLower Price TargetBuy ➝ Buy$154.00 ➝ $149.00High
i
2/6/2018SVB LeerinkBoost Price TargetOutperform ➝ Outperform$153.00 ➝ $157.00High
i
2/5/2018Cantor FitzgeraldReiterated RatingBuy ➝ Buy$208.00 ➝ $192.00Medium
i
Rating by Elemer Piros at Cantor Fitzgerald
1/23/2018SVB LeerinkReiterated RatingBuy$153.00Medium
i
12/14/2017The Goldman Sachs GroupUpgradeNeutral ➝ Buy$174.00Medium
i
12/4/2017Cantor FitzgeraldSet Price TargetBuy$208.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
11/20/2017Cantor FitzgeraldReiterated RatingBuy$208.00N/A
i
Rating by Elemer Piros at Cantor Fitzgerald
11/14/2017Bank of AmericaLower Price TargetBuy$160.00 ➝ $158.00N/A
i
10/6/2017The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$124.00N/A
i
10/2/2017Cantor FitzgeraldReiterated RatingOverweight$208.00Medium
i
Rating by Elemer Piros at Cantor Fitzgerald
10/2/2017CowenReiterated RatingOutperform$165.00Medium
i
10/2/2017SVB LeerinkReiterated RatingOutperform$160.00 ➝ $153.00Medium
i
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$154.00Medium
i
8/10/2017SVB LeerinkReiterated RatingOutperform$162.00 ➝ $160.00Medium
i
8/8/2017Cantor FitzgeraldSet Price TargetBuy$208.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
8/8/2017Maxim GroupDowngradeBuy ➝ Hold$61.00High
i
Rating by Gabrielle Zhou at Maxim Group
8/7/2017Maxim GroupSet Price TargetBuy$135.00Low
i
Rating by Gabrielle Zhou at Maxim Group
6/8/2017Maxim GroupSet Price TargetBuy$135.00High
i
Rating by Gabrielle Zhou at Maxim Group
5/25/2017Maxim GroupReiterated RatingBuy$135.00Low
i
Rating by Lauren Chung at Maxim Group
5/9/2017Cantor FitzgeraldReiterated RatingBuy$208.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
4/20/2017Maxim GroupInitiated CoverageBuy ➝ Buy$135.00Medium
i
2/22/2017The Goldman Sachs GroupReiterated RatingBuy$185.00N/A
i
2/7/2017Piper Jaffray CompaniesSet Price TargetBuy$147.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
2/7/2017Cantor FitzgeraldSet Price TargetBuy$208.00N/A
i
Rating by Elemer Piros at Cantor Fitzgerald
2/6/2017CowenSet Price TargetBuy$135.00N/A
i
Rating by Phil Nadeau at Cowen Inc
1/13/2017The Goldman Sachs GroupInitiated CoverageBuy$189.00N/A
i
12/7/2016CowenReiterated RatingOutperform$135.00N/A
i
Rating by Phil Nadeau at Cowen Inc
12/5/2016Cantor FitzgeraldBoost Price TargetBuy$182.00 ➝ $208.00N/A
i
Rating by elemer piros at Cantor Fitzgerald
12/4/2016Piper Jaffray CompaniesReiterated RatingOverweight$147.00N/A
i
Rating by joshua schimmer at Piper Jaffray Companies
11/3/2016SVB LeerinkReiterated RatingBuy$162.00N/A
i
Rating by P. Matteis at SVB Leerink LLC
10/7/2016The Goldman Sachs GroupInitiated CoverageBuy$189.00N/A
i
10/4/2016SVB LeerinkInitiated CoverageOutperform$162.00N/A
i
Rating by Paul Matteis at SVB Leerink LLC
9/27/2016CowenReiterated RatingOutperform$135.00N/A
i
Rating by Phil Nadeau at Cowen Inc
9/26/2016Piper Jaffray CompaniesReiterated RatingOverweight$147.00N/A
i
Rating by joshua schimmer at Piper Jaffray Companies
9/26/2016Cantor FitzgeraldBoost Price TargetBuy$165.00 ➝ $182.00N/A
i
Rating by elemer piros at Cantor Fitzgerald
9/25/2016Morgan StanleyBoost Price TargetOverweight$152.00 ➝ $160.00N/A
i
Rating by Andrew Berens at Morgan Stanley
9/8/2016Cantor FitzgeraldSet Price TargetBuy$165.00N/A
i
Rating by elemer piros at Cantor Fitzgerald
8/26/2016Numis SecuritiesUpgradeSell ➝ HoldN/A
i
8/13/2016Piper Jaffray CompaniesReiterated RatingOverweight$147.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
8/9/2016CowenReiterated RatingBuy$135.00N/A
i
Rating by Phil Nadeau at Cowen Inc
8/9/2016Cantor FitzgeraldLower Price TargetBuy$181.00 ➝ $165.00N/A
i
7/18/2016Bank of AmericaReiterated RatingBuy$153.00N/A
i
Rating by Tazeen Ahmad at Bank of America Co.
6/29/2016SVB LeerinkReiterated RatingOutperform$130.00N/A
i
Rating by Paul Matteis at SVB Leerink LLC
6/28/2016The Goldman Sachs GroupLower Price Target$135.00 ➝ $105.00N/A
i
6/28/2016Morgan StanleyBoost Price TargetOverweight$149.00 ➝ $152.00N/A
i
Rating by Andrew Berens at Morgan Stanley
6/28/2016Cantor FitzgeraldReiterated RatingBuyN/A
i
6/27/2016CowenReiterated RatingBuy$135.00N/A
i
Rating by Phil Nadeau at Cowen Inc
6/27/2016SVB LeerinkBoost Price TargetBuy$138.00N/A
i
Rating by Paul Matteis at SVB Leerink LLC
6/27/2016Janney Montgomery ScottInitiated CoverageSellN/A
i
6/26/2016Piper Jaffray CompaniesReiterated RatingBuy$147.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
6/21/2016SVB LeerinkReiterated RatingBuy$130.00N/A
i
Rating by Paul Matteis at SVB Leerink LLC
6/10/2016Morgan StanleyReiterated RatingBuy$149.00N/A
i
Rating by Andrew Berens at Morgan Stanley
6/2/2016Cantor FitzgeraldInitiated CoverageBuy$181.00N/A
i
Rating by E. Piros at Cantor Fitzgerald
5/5/2016SVB LeerinkReiterated RatingOutperform$130.00N/A
i
Rating by Paul Matteis at SVB Leerink LLC
4/19/2016SVB LeerinkReiterated RatingOutperform$130.00N/A
i
Rating by Paul Matteis at SVB Leerink LLC
4/17/2016CowenReiterated RatingBuyN/A
i
Rating by Phil Nadeau at Cowen Inc
4/1/2016Piper Jaffray CompaniesReiterated RatingOverweight$147.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
3/20/2016Piper Jaffray CompaniesReiterated RatingBuy$147.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
3/16/2016Bank of AmericaReiterated RatingBuyN/A
i
Rating by Tazeen Ahmad at Bank of America Co.
3/15/2016CowenReiterated RatingBuy$135.00N/A
i
Rating by Phil Nadeau at Cowen Inc
3/14/2016Piper Jaffray CompaniesReiterated RatingBuyN/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
3/14/2016Morgan StanleyReiterated RatingBuyN/A
i
Rating by Andrew Berens at Morgan Stanley
3/14/2016SVB LeerinkBoost Price TargetOutperform$100.00 ➝ $130.00N/A
i
Rating by Paul Matteis at SVB Leerink LLC
3/14/2016Roth CapitalBoost Price TargetBuy$130.00 ➝ $160.00N/A
i
3/3/2016Numis SecuritiesInitiated CoverageSellN/A
i
2/18/2016SVB LeerinkLower Price TargetOutperform$129.00 ➝ $100.00N/A
i
Rating by Paul Matteis at SVB Leerink LLC
(Data available from 1/15/2016 forward)
GW Pharmaceuticals logo
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, Dravet syndrome, and Lennox-Gastaut syndrome, as well as in phase III clinical trials for the treatment of tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of for schizophrenia, autism spectrum disorder, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.
Read More

Today's Range

Now: $135.73
$134.79
$141.50

50 Day Range

MA: $124.11
$114.91
$140.08

52 Week Range

Now: $135.73
$67.98
$144.00

Volume

379,913 shs

Average Volume

442,914 shs

Market Capitalization

$4.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.15

Frequently Asked Questions

What sell-side analysts currently cover shares of GW Pharmaceuticals?

The following Wall Street research analysts have issued reports on GW Pharmaceuticals in the last year: Bank of America Co., Cantor Fitzgerald, Citigroup Inc., Evercore ISI, Guggenheim, HC Wainwright, Needham & Company LLC, Northland Securities, Oppenheimer Holdings Inc., Raymond James, Stifel Nicolaus, The Goldman Sachs Group, Inc., TheStreet, and Zacks Investment Research.

What is the current price target for GW Pharmaceuticals?

11 Wall Street analysts have set twelve-month price targets for GW Pharmaceuticals in the last year. Their average twelve-month price target is $188.09, suggesting a possible upside of 38.6%. Evercore ISI has the highest price target set, predicting GWPH will reach $275.00 in the next twelve months. Northland Securities has the lowest price target set, forecasting a price of $128.00 for GW Pharmaceuticals in the next year.

What is the current consensus analyst rating for GW Pharmaceuticals?

GW Pharmaceuticals currently has 3 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GWPH will outperform the market and that investors should add to their positions of GW Pharmaceuticals.

What other companies compete with GW Pharmaceuticals?

How do I contact GW Pharmaceuticals' investor relations team?

GW Pharmaceuticals' physical mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company's listed phone number is 44-12-2326-6800 and its investor relations email address is sschultz@gwpharm.com. The official website for GW Pharmaceuticals is www.gwpharm.com.